Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

Please reload

Recent Posts

LIfT BioSciences Wins the Support of The European Institute for Innovation & Technology

February 12, 2019

1/7
Please reload

Featured Posts

LIfT BioSciences Gains Initial Funding into Pancreatic Cancer Research

January 31, 2017

LIfT BioSciences has successfully secured initial funding into its potentially breakthrough Cell Therapy for Pancreatic Cancer. The funding has come from a Top 20 Major BioPharma Company, who for the time being wishes to remain anonymous.

 

The research aims to demonstrate that LIfT BioSciences Leukocyte Infusion Therapy (LIfT) can selectively destroy pancreatic cancer cell lines in-vitro, and to develop an assay that allows this Cancer Killing Activity (CKA) to be accurately monitored. If successful, LIfT BioSciences will move to testing other Cancer Cell types and with move its primary target, Pancreatic Ductal Adenocarcinoma (PDAC) to first in-human Clinical Trials.

 

Professor Farzin Farzaneh D.Phil., FRCPath., FRSB, of King's College London is leading the research with LIfT BioSciences. Kings College London were partnered with LIfT BioSciences through the Medcity initiative to bring together SME’s with world leading London research institutions.

 

Appropriately selected leukocytes have already proven effective in-vitro for killing cervical and bladder cancer cells and in-vivo for eliminating prostate cancer and sarcoma in mice. The team are optimistic that similar results can be achieved in Pancreatic Cancer cells, as the first step in their mission to cure Pancreatic Cancer by 2021.

 

Currently 97% of Patients with Pancreatic Cancer will be dead within 5 years in the UK. Pancreatic Ductal Adenocarcinoma (PDAC) has 4.6m median survival in the UK. Survival rates have remained largely unchanged for 40 years. (Source: Pancreatic Cancer Action).

 

Alex Blyth, CEO at LIfT BioSciences, commented that “the funding from a major Biopharma company like this is a real endorsement of the potential we all see in LIfT, and the very different approach to Cancer that we are taking by utilising the Innate Immune System to potentially cure Cancers. We are all very excited about what this could mean for patients”.

Share on Facebook
Share on Twitter
Please reload

Follow Us

I'm busy working on my blog posts. Watch this space!

Please reload

Search By Tags